Literature DB >> 27915170

Optimization of substituted imidazobenzodiazepines as novel asthma treatments.

Rajwana Jahan1, Michael Rajesh Stephen1, Gloria S Forkuo1, Revathi Kodali1, Margaret L Guthrie1, Amanda N Nieman1, Nina Y Yuan1, Nicolas M Zahn1, Michael M Poe1, Guanguan Li1, Olivia B Yu1, Gene T Yocum2, Charles W Emala2, Douglas C Stafford1, James M Cook3, Leggy A Arnold4.   

Abstract

We describe the synthesis of analogs of XHE-III-74, a selective α4β3γ2 GABAAR ligand, shown to relax airway smooth muscle ex vivo and reduce airway hyperresponsiveness in a murine asthma model. To improve properties of this compound as an asthma therapeutic, a series of analogs with a deuterated methoxy group in place of methoxy group at C-8 position was evaluated for isotope effects in preclinical assays; including microsomal stability, cytotoxicity, and sensorimotor impairment. The deuterated compounds were equally or more metabolically stable than the corresponding non-deuterated analogs and increased sensorimotor impairment was observed for some deuterated compounds. Thioesters were more cytotoxic in comparison to other carboxylic acid derivatives of this compound series. The most promising compound 16 identified from the in vitro screens also strongly inhibited smooth muscle constriction in ex vivo guinea pig tracheal rings. Smooth muscle relaxation, determined by reduction of airway hyperresponsiveness with a murine ovalbumin sensitized and challenged model, showed that 16 was efficacious at low methacholine concentrations. However, this effect was limited due to suboptimal pharmacokinetics of 16. Based on these findings, further analogs of XHE-III-74 will be investigated to improve in vivo metabolic stability while retaining the efficacy at lung tissues involved in asthma pathology.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Airway hyperresponsiveness; Airway smooth muscle; Asthma; Deuterated compounds; GABA(A) receptor; XHE-III-74

Mesh:

Substances:

Year:  2016        PMID: 27915170      PMCID: PMC5253108          DOI: 10.1016/j.ejmech.2016.11.045

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  26 in total

1.  Costs of asthma in the United States: 2002-2007.

Authors:  Sarah Beth L Barnett; Tursynbek A Nurmagambetov
Journal:  J Allergy Clin Immunol       Date:  2011-01       Impact factor: 10.793

2.  The point mutation gamma 2F77I changes the potency and efficacy of benzodiazepine site ligands in different GABAA receptor subtypes.

Authors:  Joachim Ramerstorfer; Roman Furtmüller; Elisabeth Vogel; Sigismund Huck; Werner Sieghart
Journal:  Eur J Pharmacol       Date:  2010-03-19       Impact factor: 4.432

3.  Airway epithelium is a predominant source of endogenous airway GABA and contributes to relaxation of airway smooth muscle tone.

Authors:  George Gallos; Elizabeth Townsend; Peter Yim; Laszlo Virag; Yi Zhang; Dingbang Xu; Matthew Bacchetta; Charles W Emala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-11-30       Impact factor: 5.464

4.  GABA (A) receptor subunits RNA expression in mice peritoneal macrophages modulate their IL-6/IL-12 production.

Authors:  Maria Guadalupe Reyes-García; Francisca Hernández-Hernández; Beatriz Hernández-Téllez; Fernando García-Tamayo
Journal:  J Neuroimmunol       Date:  2007-06-27       Impact factor: 3.478

5.  GABAA receptors are expressed and facilitate relaxation in airway smooth muscle.

Authors:  Kentaro Mizuta; Dingbang Xu; Yaping Pan; George Comas; Joshua R Sonett; Yi Zhang; Reynold A Panettieri; Jay Yang; Charles W Emala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-04-11       Impact factor: 5.464

6.  A GABAergic system in airway epithelium is essential for mucus overproduction in asthma.

Authors:  Yun-Yan Xiang; Shuhe Wang; Mingyao Liu; Jeremy A Hirota; Jingxin Li; William Ju; Yijun Fan; Margaret M Kelly; Bin Ye; Beverley Orser; Paul M O'Byrne; Mark D Inman; Xi Yang; Wei-Yang Lu
Journal:  Nat Med       Date:  2007-06-24       Impact factor: 53.440

Review 7.  Regular treatment with salmeterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 8.  Regular treatment with formoterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

9.  GABA Potency at GABA(A) Receptors Found in Synaptic and Extrasynaptic Zones.

Authors:  Martin Mortensen; Bijal Patel; Trevor G Smart
Journal:  Front Cell Neurosci       Date:  2012-01-20       Impact factor: 5.505

Review 10.  A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model.

Authors:  Terry Clayton; Michael M Poe; Sundari Rallapalli; Poonam Biawat; Miroslav M Savić; James K Rowlett; George Gallos; Charles W Emala; Catherine C Kaczorowski; Douglas C Stafford; Leggy A Arnold; James M Cook
Journal:  Int J Med Chem       Date:  2015-11-10
View more
  8 in total

1.  Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABAA Receptor Modulators.

Authors:  Gloria S Forkuo; Amanda N Nieman; Nina Y Yuan; Revathi Kodali; Olivia B Yu; Nicolas M Zahn; Rajwana Jahan; Guanguan Li; Michael Rajesh Stephen; Margaret L Guthrie; Michael M Poe; Benjamin D Hartzler; Ted W Harris; Gene T Yocum; Charles W Emala; Douglas A Steeber; Douglas C Stafford; James M Cook; Leggy A Arnold
Journal:  Mol Pharm       Date:  2017-05-01       Impact factor: 4.939

2.  A Novel Orally Available Asthma Drug Candidate That Reduces Smooth Muscle Constriction and Inflammation by Targeting GABAA Receptors in the Lung.

Authors:  Gloria S Forkuo; Amanda N Nieman; Revathi Kodali; Nicolas M Zahn; Guanguan Li; M S Rashid Roni; Michael Rajesh Stephen; Ted W Harris; Rajwana Jahan; Margaret L Guthrie; Olivia B Yu; Janet L Fisher; Gene T Yocum; Charles W Emala; Douglas A Steeber; Douglas C Stafford; James M Cook; Leggy A Arnold
Journal:  Mol Pharm       Date:  2018-04-02       Impact factor: 4.939

3.  Development of Inhaled GABAA Receptor Modulators to Improve Airway Function in Bronchoconstrictive Disorders.

Authors:  Nicolas M Zahn; M S Rashid Roni; Gene T Yocum; Michelle J Meyer; Daniel A Webb; Md Yeunus Mian; James M Cook; Douglas C Stafford; Charles W Emala; Leggy A Arnold
Journal:  ACS Pharmacol Transl Sci       Date:  2022-02-01

4.  Comparative pharmacodynamic and pharmacokinetic study of MIDD0301 and its (S) enantiomer.

Authors:  M S Rashid Roni; Nicolas M Zahn; Gene T Yocum; Daniel A Webb; Md Yeunus Mian; Michelle J Meyer; Anika S Tylek; James M Cook; Charles W Emala; Douglas C Stafford; Leggy A Arnold
Journal:  Drug Dev Res       Date:  2022-03-04       Impact factor: 5.004

5.  Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma Models.

Authors:  Nicolas M Zahn; Brandon N Mikulsky; M S Rashid Roni; Gene T Yocum; Md Yeunus Mian; Daniel E Knutson; James M Cook; Charles W Emala; Douglas C Stafford; Leggy A Arnold
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-02

6.  Argon reduces the pulmonary vascular tone in rats and humans by GABA-receptor activation.

Authors:  Said Suleiman; Sergej Klassen; Ira Katz; Galina Balakirski; Julia Krabbe; Saskia von Stillfried; Svetlana Kintsler; Till Braunschweig; Aaron Babendreyer; Jan Spillner; Sebastian Kalverkamp; Thomas Schröder; Manfred Moeller; Mark Coburn; Stefan Uhlig; Christian Martin; Annette D Rieg
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

7.  Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability.

Authors:  Daniel E Knutson; Revathi Kodali; Branka Divović; Marco Treven; Michael R Stephen; Nicolas M Zahn; Vladimir Dobričić; Alec T Huber; Matheus A Meirelles; Ranjit S Verma; Laurin Wimmer; Christopher Witzigmann; Leggy A Arnold; Lih-Chu Chiou; Margot Ernst; Marko D Mihovilovic; Miroslav M Savić; Werner Sieghart; James M Cook
Journal:  J Med Chem       Date:  2018-03-06       Impact factor: 8.039

8.  A Structure-Activity Relationship Comparison of Imidazodiazepines Binding at Kappa, Mu, and Delta Opioid Receptors and the GABAA Receptor.

Authors:  Guanguan Li; Amanda N Nieman; Md Yeunus Mian; Nicolas M Zahn; Brandon N Mikulsky; Michael M Poe; Kashi R Methuku; Yongfeng Liu; James M Cook; Douglas C Stafford; Leggy A Arnold
Journal:  Molecules       Date:  2020-08-25       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.